approval
saveRINVOQ (UPADACITINIB) — FDA approval
community read0 votes
Sponsor: ABBVIE. Form: TABLET, EXTENDED RELEASE. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalRINVOQ (UPADACITINIB) — FDA approvalOct 10, 2025 · 359d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalAug 12, 2025 · 418d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalApr 28, 2025 · 524d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalMar 26, 2025 · 557d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalApr 26, 2024 · 891d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalNov 14, 2023 · 1055d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalJun 22, 2023 · 1200d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalMay 18, 2023 · 1235d ago
same company · ±60 days · 6
- approvalupadacitinib tartrate ER: RINVOQ (UPADACITINIB) — FDA approvalApr 26, 2024
- approvalupadacitinib: RINVOQ LQ (UPADACITINIB) — FDA approvalApr 26, 2024
- approvalIMBRUVICA (IBRUTINIB) — FDA approvalMay 9, 2024
- approvalIMBRUVICA (IBRUTINIB) — FDA approvalMay 9, 2024
- approvalIMBRUVICA (IBRUTINIB) — FDA approvalMay 9, 2024
- approvaldivalproex sodium DR: DEPAKOTE (DIVALPROEX SODIUM) — FDA approvalMar 18, 2024
comments(0)
5-min edit window · permanent after that